Wolfe Research Begins Coverage on Structure Therapeutics (NASDAQ:GPCR)

Wolfe Research initiated coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a note issued to investors on Thursday, Marketbeat.com reports. The firm set a “peer perform” rating on the stock.

Several other brokerages also recently issued reports on GPCR. Citigroup reiterated an “outperform” rating on shares of Structure Therapeutics in a research report on Friday, December 12th. William Blair reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. The Goldman Sachs Group upgraded Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. Guggenheim increased their price target on Structure Therapeutics from $90.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Finally, Wall Street Zen raised Structure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $110.00.

Structure Therapeutics Stock Down 0.6%

Shares of NASDAQ:GPCR opened at $45.92 on Thursday. The company’s 50-day moving average price is $68.79 and its 200 day moving average price is $51.39. The company has a market cap of $3.25 billion, a PE ratio of -58.13 and a beta of -1.80. Structure Therapeutics has a fifty-two week low of $13.22 and a fifty-two week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.14). As a group, equities analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its position in Structure Therapeutics by 25.2% in the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock worth $495,334,000 after purchasing an additional 1,432,797 shares during the period. Avoro Capital Advisors LLC increased its position in shares of Structure Therapeutics by 21.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after purchasing an additional 1,150,000 shares during the period. Janus Henderson Group PLC raised its stake in shares of Structure Therapeutics by 14.4% in the 4th quarter. Janus Henderson Group PLC now owns 5,090,148 shares of the company’s stock worth $354,006,000 after buying an additional 641,322 shares in the last quarter. BVF Inc. IL raised its stake in shares of Structure Therapeutics by 8.6% in the 4th quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock worth $241,966,000 after buying an additional 275,105 shares in the last quarter. Finally, Morgan Stanley lifted its holdings in shares of Structure Therapeutics by 261.4% in the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after buying an additional 1,510,093 shares during the period. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.